Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.73 |
| ▸ | DUSP1 | P28562 | 5/20 | 0.69 |
| ▸ | THRB | P10828 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513763 | 0.92 | MAPT (0.77) | MAPTDUSP1THRBGAAHPGD | |
| SCHEMBL4518500 | 0.88 | MAPT (0.75) | MAPTDUSP1THRBGAAHPGD | |
| SCHEMBL4514921 | 0.86 | DUSP1 (0.72) | MAPTDUSP1GAAHPGDHSD17B10 | |
| SCHEMBL4517932 | 0.83 | HPGD (0.82) | MAPTDUSP1THRBGAAHPGD | |
| SCHEMBL17544297 | 0.82 | MAPT (0.79) | MAPTDUSP1THRBGAAHPGD | |
| SCHEMBL30402162 | 0.82 | MAPT (0.79) | MAPTDUSP1THRBGAAHPGD | |
| SCHEMBL4501249 | 0.82 | HPGD (0.72) | MAPTDUSP1THRBGAAHPGD | |
| SCHEMBL4523637 | 0.82 | HPGD (0.66) | MAPTDUSP1GAAHPGDHSD17B10 | |
| SCHEMBL4513229 | 0.81 | TP53 (0.65) | MAPTDUSP1GAAHPGDHSD17B10 | |
| SCHEMBL2243823 | 0.78 | MAPT (0.77) | MAPTTHRBHPGDHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
| EP-1933834-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042816-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | MAPT 270/4885DUSP1 892/4885THRB 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.